News Releases

Cannabix Technologies Correlates THC in Breath and Blood using Proprietary Sample Collection and Analysis Hardware in Experimental Study

May 9, 2022

Vancouver, British Columbia, May 9, 2022 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports it has successfully tested a supplemental version of its FAIMS technology for detection of ∆9-tetrahydrocannabinol (“THC”) and related analytes in human breath in an independent experimental study. The study showed excellent correlation between breath samples collected and analyzed with Cannabix hardware and blood plasma levels of THC. The Company’s handheld Breath Collection Unit (“BCU”, Fig. 1) and newly developed laboratory “MS Breath Sampler” (Fig. 2) were used together to provide a new ground-breaking method for drug detection that complements gold-standard mass spectrometry (MS), and has the potential to significantly decrease laboratory analysis times and operating costs, while maintaining sensitive, precise results. The Company has developed a unique breath analysis system, capable of sampling breath for low volatility analytes, like THC, and can be completed within seconds, with no sample preparation needed.

This novel system, developed by Cannabix scientists and engineers was recently tested in an independent study conducted by pioneering scientist, Dr. Phillip Olla, of Audacia Bioscience in Ontario. Dr. Olla is one of only a handful of scientists globally who has historically ever conducted THC analysis in blood and breath.

THC in Breath & Blood Data

The experimental study included 6 subjects with a 60%-40% between men and women with an average age of 23 years. Breath and blood samples were taken simultaneously at the baseline (a timepoint before smoking cannabis) and incremental time points (after smoking cannabis) out to 1 hour and 40 minutes after smoking (it should be noted that Cannabix has been able to detect and confirm THC in breath using the same hardware out to 4 hours after smoking in recent lab testing). Breath samples were taken with the Cannabix BCU, and analyzed using the Cannabix Mass Spectrometer (MS) Breath Sampler coupled to Thermo TSQ Quantum Ultra MS. THC fragments were analyzed using Thermo Xcalibur software and areas under the chromatogram curves (AUC) were determined using the software’s detection feature. Blood serum samples were analyzed at Analytical Facility for Bioactive Molecules at The Hospital for Sick Children (Toronto, ON, Canada) using LC/MS/MS, according to conventional standard operating procedures.

The resulting data (see Fig. 3 below) provides an excellent correlation between human breath samples collected and analyzed with the Cannabix hardware and blood plasma levels of THC. Furthermore, the data from this experimental study supports literature by showing the same trends in THC metabolism, and that blood and breath levels of THC over time correlate with a high degree of accuracy - within one or two hours after smoking (Fig. 4). Readers should note that blood is currently the standard measurement for law enforcement, toxicologists and evidence used in courts of law. The BCU is also being used with the Cannabix portable FAIMS THC detection unit.

Cannabix Sr. Analytical Chemist, Dr. Jared Boock stated, “This study shows the capability of the Cannabix Breath Analysis system to easily and rapidly collect breath samples in the field and correlate to blood THC levels. Law enforcement and toxicologists rely on gold standard mass spectrometry results to confirm drug presence in blood. We have developed a truly ground-breaking breath analysis tool capable of breath sampling for THC, within seconds, with no sample preparation needed. Furthermore, we were able to store, ship and analyze samples for up to 40 hours after they were taken in the field.”

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.